Clinical Trial Update: Effect of Rosuvastatin on Systemic Sclerosis-related Pulmonary Hypertension [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating rosuvastatin for systemic sclerosis-related pulmonary hypertension has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Hypertension
• Systemic Sclerosis

Drugs mentioned

• Rosuvastatin (rosuvastatin)

Snippet

Sponsor: University of Alexandria | Conditions: Systemic Sclerosis | Phase 3 | Status: COMPLETED